FDA-Approved Drugs
This is a list of prescription drugs approved by the FDA for Dry Eye Disease or, where indicated, related ocular surface diseases.
For drugs that are awaiting FDA review or are in the development process, please see Drug Pipeline.
-
DRUG: Lotilaner 0.25%
COMPANY: Tarsus Pharmaceuticals
INDICATION: Demodex blepharitis
-
DRUG: Cyclosporine ophthalmic solution 0.1%
COMPANY: Harrow
INDICATION: For treatment of the signs and symptoms of dry eye disease.
(Note: Previously known as CyclASol.)
-
DRUG: Perfluorohexyloctane ophthalmic solution
COMPANY: Bausch & Lomb / Novaliq
INDICATION: For treatment of the signs and symptoms of dry eye disease.
-
DRUG: Varenicline solution - nasal spray 0.03mg
COMPANY: Oyster Point Pharma (now owned by Viatris)
INDICATION: For treatment of the signs and symptoms of dry eye disease.
-
DRUG: Loteprednol etabonate ophthalmic suspension 0.25%
COMPANY: Alcon (originally Kala Pharmaceutical)
INDICATION: For short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease.
-
DRUG: Cyclosporine ophthalmic solution 0.09%
COMPANY: Sun Pharmaceuticals.
INDICATION: To increase tear production in patients with keratoconjunctivitis sicca (dry eye).
-
DRUG: Cenegermin, a/k/a recombinant human nerve growth factor
COMPANY: Dompé.
INDICATION: Orphan drug designation for neurotrophic keratitis.
-
DRUG: Lifitegrast 5%
COMPANY: Bausch & Lomb (originally Shire, then Novartis)
INDICATION: For treatment of signs and symptoms of dry eye disease.
-
DRUG: Cyclosporine ophthalmioc emulsion 0.05%
COMPANY: Allergan (an Abbvie company)
INDICATION: To increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with KCS.
FDA-Approved Drugs
Below is a list of FDA-approved drugs for dry eye disease and certain related ocular surface disease indications.
For drugs that are awaiting FDA review or are in the development process, please see Pipeline.